ICD Research's 'OSI Pharmaceuticals, Inc.: Company Profile and SWOT Analysis' contains in depth information and data about the company and its operations. The profile contains a company overview, business description, SWOT analysis, key facts, information on products and services, details of locations and subsidiaries, plus information on key news events affecting the company.
This SWOT analysis and company profile is a crucial resource for industry executives and anyone looking to gain a better understanding of the company's business.
ICD Research's 'OSI Pharmaceuticals, Inc.: Company Profile and SWOT Analysis' report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format.
ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Examines and identifies key information and issues about 'OSI Pharmaceuticals, Inc.' for business intelligence requirements
Studies and presents the company's strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported
The profile also contains information on business operations, company history, major products and services, prospects, key employees, locations and subsidiaries
Reasons To Buy
Quickly enhance your understanding of the company
Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry
Recognize potential partnerships and suppliers
OSI Pharmaceuticals, Inc. (OSI), a subsidiary of Astellas US Holding, Inc., is a biopharmaceutical company,focusingon the discovery, development and commercialization of innovative molecular targeted therapies to address major unmet medical needs in oncology, diabetes and obesity. The company's flagship product is Tarceva, a small molecule inhibitor of the epidermal growth factor receptor (EGFR). The company's Tarcevais marketed for the treatment of non-small cell lung cancer and pancreatic cancer..OSIis headquartered in Melville,New York, the US.